|Bid||249.00 x 1100|
|Ask||249.30 x 1100|
|Day's range||246.33 - 257.30|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||264.20|
Novavax (NASDAQ: NVAX) has found hitting target dates for regulatory filings is easier said than done. The company delayed its planned submissions for Emergency Use Authorization for COVID-19 vaccine NVX-CoV2373 earlier this year. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli talk about whether Novavax could experience further delays and what it might mean for the stock.
Dr. Arthur Caplan, NYU Langone Health, Division of Medical Ethics at NYU School of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus vaccines and booster shots.
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility